In the present mini-pig study, we developed a protocol for simulating moderate ischemic cerebral stroke and evaluated the efficacy of the autologous, genetically enriched leucoconcentrate (GEL) producing recombinant VEGF, GDNF, and NCAM in the acute phase (intravenous infusion 4 h after stroke modelling) and preventive phase (intravenous infusion of GEL 2 days before stroke modelling) of stroke gene therapy (Figure 1). This evidence concerns the gene NCAM1 and Stroke.